Last reviewed · How we verify

ASP1650 — Competitive Intelligence Brief

ASP1650 (ASP1650) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: EP4 receptor antagonist. Area: Oncology.

phase 2 EP4 receptor antagonist EP4 (prostaglandin E receptor 4) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ASP1650 (ASP1650) — Astellas Pharma Global Development, Inc.. ASP1650 is a selective antagonist of the prostaglandin E receptor EP4, which reduces inflammatory signaling and immune suppression in the tumor microenvironment.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ASP1650 TARGET ASP1650 Astellas Pharma Global Development, Inc. phase 2 EP4 receptor antagonist EP4 (prostaglandin E receptor 4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (EP4 receptor antagonist class)

  1. Astellas Pharma Global Development, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ASP1650 — Competitive Intelligence Brief. https://druglandscape.com/ci/asp1650. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: